Kornimate/medical-research-clean huggingface dataset:
early stop(ruling) of the antibiotic treatment during pneumopathies d' inhalation

Conditions: Aspiration Pneumonia

Summary: the two most common consequences resulting from aspiration are chemical pneumonitis and bacterial aspiration pneumonia. both entities present with comparable clinical signs and symptoms. in the absence of a reliable clinical or biological marker to differentiate between these two conditions, most patients with suspected aspiration are treated empirically with antibiotics. de-escalation of initial antibiotic treatment is encouraged based on the results of microbiological results, usually performed before starting antimicrobial treatment. however, in most hospitals, 48-72h are required to obtain the results of microbiological cultures, and to de-escalate empirical large spectrum antibiotic treatment. the use of the unyvero®, a multiplex pcr-based testing system, for detection of respiratory bacterial pathogens would allow decreasing the percentage of patients with aspiration syndrome who will receive unappropriated antibiotic treatment at day 3.


Eligibility criteria:
inclusion criteria: * presence of risk factors for aspiration : * known or likely swallowing dysfunction, * altered consciousness, * cardiac arrest, * difficult intubation * witnessed aspiration * symptoms and signs suggestive of lower respiratory tract pathology * temperature ≥38.5°c or \<36°c * leukocyte count ≥10 000/µl or \<1500/µl * purulent sputum or tracheal aspirate. * new radiographic infiltrate on chest x-ray * tracheal intubation and mechanical ventilation since less than 48 hours exclusion criteria: * pregnant women * refuse to participate to the study * no informed consent * documented bacteremia * septic shock * severe immunosuppression: leukocytes\ 0.5 mg/kg day for at least one month during the last three months). * moribund patients (saps ii \>90).

Keywords: aspiration pneumonia invasive ventilation pcr antibiotics tracheal aspirate
coronary flow during rapid heart rates

Conditions: Ventricular Tachycardia; Coronary Artery Disease; Heart Failure; Coronary Microvascular Dysfunction; Coronary Microvascular Disease

Summary: the goal of this observational study is to learn about the factors which determine how well ventricular tachycardia (vt) is tolerated. the main questions it aims to answer are: 1. what impact does coronary artery disease have on the ability for a patient to tolerate vt? 2. does treatment of coronary artery disease with stents improve the tolerability of vt? participants who are undergoing a clinically indicated coronary angiogram or coronary angioplasty procedure will have measurements of blood pressure, coronary pressure and coronary flow made during pacing at a range of heart rates.

ventricular tachycardia (vt) is a common and life-threatening arrhythmia that occurs in people with heart problems. some patients who develop this arrhythmia remain very stable with very little symptoms while others become unstable with low blood pressure or even sudden death. it is not known why some people tolerate the arrhythmia well and others do not. if vt is not tolerated then current practice is to offer an implantable cardioverter defibrillator (icd) which can deliver a shock to the heart if dangerous heart rhythms are detected. while shocks can be life-saving, they are also harmful, including causing psychological distress. icds also frequently deliver shocks when they are not needed. if research could identify which factors predispose a person to be stable or unstable in vt, this would allow doctors to help them in a range of ways. one way would be to treat patients to improve the tolerance of vt, so avoiding the need for an icd. another would be to assess the the risk of instability and so allow a patient-centred decision on whether an icd is needed. in this study the investigators plan to recruit patients who are referred for a coronary angiogram. during the angiogram, the investigators will stimulate the heart at a range of fast heart rates and measure their blood pressure and flow in their coronary arteries. in patients who undergo stenting for a coronary stenosis, the investigators will also make these measurements after stenting so they can see if there is any difference. by recruiting a range of different cardiology patients, the investigators will be able to assess which factors contribute to stability during vt.

Eligibility criteria:
inclusion criteria: * able to give valid consent * referred for coronary angiography or coronary angioplasty * suitable for percutaneous physiological interrogation and pci when clinically indicated exclusion criteria: * unable to give valid consent * pregnant or breastfeeding women * unstable coronary artery disease (acute coronary syndrome) * severe multivessel coronary artery disease suitable for coronary artery bypass grafting * severe heart valve disease * severe (nyha iv) heart failure

Keywords: ventricular tachycardia coronary artery disease heart failure coronary microvascular dysfunction coronary microvascular disease percutaneous coronary intervention implantable cardioverter defibrillator
collecting real-life data for the updated tena smartcare change indicator.

Conditions: Urinary Incontinence

Summary: this study is an explorative, open, single-arm clinical investigation to collect real-life measurement data in order to assess the mathematical algorithms involved in tena smartcare change indicator.

the purpose of this exploratory clinical investigation is to evaluate safety and to collect real-life measurement data using the updated tena smartcare change indicator. the collected data will be used to assess and develop the device related algorithms. these algorithms have been tested in a laboratory setting but real-life measurement data are to be collected to the aid in further product development.

Eligibility criteria:
inclusion criteria: * be willing and able to provide informed consent to participate or, if unable to provide such consent, have a legal representative who is willing and able to provide informed consent on behalf of the resident. * be 18 years of age of older. * be cared for at the investigation site. * suffer from urinary incontinence. * be current user of tena slip, flex, pants or comfort incontinence products or during the course of the study be willing to become user of tena slip flex, pants or comfort incontinence products. * if applicable, be on a stable regimen of medications for urinary incontinence. exclusion criteria: * have frequent (daily) faecal incontinence in the pad or having severe problems with faecal incontinence as determined by the investigator. * have severe incontinence product related skin problems, as defined by the globiad categorization 2b (skin loss \& infection). * have any type of indwelling or external urinary catheter(s). * be anuric. * be of childbearing potential as determined by the investigator. * be managed using another automated or digital health technology incontinence management device. * have responsive behaviors of sufficient severity, in the opinion of the care staff, to make participation impractical. * have any other condition that makes participation in the clinical investigation * have a life expectancy of less than 90 days or be in receipt of palliative/terminal care. * have participated in an investigational study of a drug, biologic, or device within 30 days prior to entering the clinical investigation or planned during the clinical investigation. * be dependent on either alcohol or recreational drugs.
carbetocin versus syntometrine in obese women undergoing elective cesarean

Conditions: Post Partum Hemorrhage

Summary: to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of postpartum hemorrhage after cesarean section

a double-blind randomized study conducted on 1200 obese pregnant subjected randomly either to single 100 μg iv dose of carbetocin (600 women) or combination of 5 iu oxytocin and 0.5 mg ergometrine (600 women) after fetal extraction and before placental removal. prevention of postpartum haemorrhage (pph) after cesarean section (cs) had been evaluated by measurement of drop of hemoglobin and hematocrit, incidence of pph and number of subjects needed additional oxytocic

Eligibility criteria:
inclusion criteria: * all participants are at 37 - 40 weeks of gestational age * noncomplicated pregnancy. * obese women with bmi \> 30. exclusion criteria: * participants with placenta previa, * coagulopathy, * preeclamptic * known sensitivity to carbetocin,oxytocin or methergine were excluded
to learn how bone structure and bone mass change after long-term ppi use

Conditions: Barrett's Esophagus; Erosive Esophagitis; Gastroesophageal Reflux Disease(GERD)

Summary: patients with severe acid reflux and/or barrett's esophagus are recommended to take proton pump inhibitors (ppis)indefinitely to prevent complications such as strictures or the development of a type of esophageal cancer. recently, some studies suggested that taking these medications on a long-term basis may affect the bone. therefore, it is important to learn whether these medications may lead to accelerated bone loss so that effective preventive measures can be developed for patients who require these medications for acid-related conditions. several studies reported that patients receiving ppis for many years may have increased risk of hip fractures. however, it is unclear whether this is because the ppis cause reduced bone density or whether the increased risk of fractures has nothing to do with ppis and is because patients who require ppis have other illnesses that cause the increased fractures. the purpose of the study is to learn how bone structure and bone mass change after long-term ppi use.

proton pump inhibitors (ppis) are among the most widely used medications. it is becoming increasingly common for patients to take these potent acid suppressants on a long-term and continuous basis for erosive esophagitis, barrett's esophagus and protection against nonsteroidal anti-inflammatory drug-related gastropathy. ppi therapy leads to elevated serum gastrin levels and may impair the absorption of calcium and food-bound vitamin b12. ppi-induced hypergastrinemia has a direct trophic effect on the parathyroid glands, leading to parathyroid hyperplasia, increased parathyroid hormone secretion and bone loss. furthermore, both calcium malabsorption and vitamin b12 deficiency are associated with reduced bone mineral density (bmd) and increased osteoporotic fracture risk. consistent with these data, recent studies revealed a positive association between ppi therapy and the risk of osteoporotic fractures. peripheral quantitative computed tomography (pqct) can provide a three-dimensional structural analysis of trabecular and cortical volumetric bmd (vbmd) and dimensions. these data are imperative for a valid assessment of the effect of chronic ppi therapy on bone strength. the investigators hypothesize that ppi therapy leads to decreased cortical and trabecular vbmd, cortical dimensions and bone strength.

Eligibility criteria:
inclusion criteria: * women between 50 to 75 years old * men between 40 to 75 years old * barrett's esophagus and erosive esophagitis diagnosed within the past three years, gerd or acid reflux, taking chronic aspirin * starting long-term ppi therapy or currently on long-term ppi therapy exclusion criteria: * pre-menopausal women * men under 40 years old

Keywords: barrett's esophagus erosive esophagitis proton pump inhibitor (ppi) bone bone density gerd ulcer prophylaxis
evaluation of the effects of different analgesics on pericoronitis pain and quality of life

Conditions: Pain; Quality of Life

Summary: pericoronitis is a painful inflammatory condition which is well known for its negative impact on quality of life of those affected. the aim of this study was to test two hypotheses: (1) that topical application of benzydamine is as effective as oral diclofenac or flurbiprofen in improving pain and quality of life of patients with pericoronitis and (2) that there would be no difference between the effects of the two oral nsaids on pain and quality of life of patients with pericoronitis


Eligibility criteria:
inclusion criteria: * young adults aged 18 years or over * diagnosed with mild pericoronitis * having semi-impacted mandibular third molar * symptoms of pain and localized swelling exclusion criteria: * smoking * history of allergy to diclofenac, flurbiprofen, benzydamine or other nsaids * use of systemic antibiotics or analgesics within 3 days before admission * the patients who had symptoms of severe pericoronitis such as fever higher than 101°f, dysphagia, trismus or facial swelling.

Keywords: pericoronitis analgesics non steroid anti-inflammatory drugs benzydamine quality of life
deferred cord clamping compared to umbilical cord milking in preterm infants

Conditions: PreTerm Birth; Intraventricular Hemorrhage

Summary: for preterm infants, deferred cord clamping has been shown to improve both short term and long-term neonatal outcomes without an established harm for both the mother and her infant.the interference with resuscitative measures for the neonate or the mother is a risk that continued to hamper the implementation of delayed cord clamping in many centers around the world.for that reason, the evidence now is seeking a time-honored, yet not adopted method of placental transfusion that involves milking of the umbilical cord.

contrary to delayed cord clamping, milking of the umbilical cord is done at a faster rate and in shorter time.recent evidence has demonstrated the efficacy and safety of umbilical cord milking for both term and preterm infants.a newer evidence comparing delayed cord clamping to umbilical cord milking in preterm infants demonstrated a higher initial hemoglobin, blood pressure and systemic blood flow in preterm infants allocated to the umbilical cord milking arm.however, concerns have been raised with regard to rapid infusion of large volume of blood in relatively shorter time predisposing to hyperperfusion injury including intraventricular hemorrhage. this is particularly problematic for preterm neonates as they are at higher risk of neurological injury. it has, though, advantage of shorter timeframe allowing for effective resuscitation of preterm neonates to start as soon as possible. thus, with countering advantages and disadvantages, the practice has not been adopted at most places. the authors planned to conduct a randomized clinical trail to compare the efficacy and safety of umbilical cord milking to deferred cord clamping in preterm infants less than 32 weeks gestation.

Eligibility criteria:
inclusion criteria: * preterm infants \< 32 weeks gestation confirmed by first trimester us exclusion criteria: * any proven or suspected congenital or chromosomal abnormalities * placenta previa or abruption * cord prolapse * known rh sensitization * fetal hydrops * monochorionic multiples
the effect of cinnamon on ovulation induction in women with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Ovulation

Summary: title: the effect of cinnamon supplementation on ovulation induction in women with polycystic ovary syndrome, jeddah 2019: randomized double-blind placebo-controlled trial phase: iii population: 118 women with polycystic ovary syndrome will be recruited from obstetrics and gynecology clinics in king abdul-aziz university hospital, jeddah 2019. subject participation duration: each participant will be followed for three months. intervention: 2g of cinnamon capsules daily will be provided. objectives: primary objective: 1. to compare the effectiveness of cinnamon supplement in combination with clomiphene citrate versus clomiphene citrate alone on ovulation in women with pcos, in king abdul-aziz university hospital in jeddah 2019. 2. to measure the difference in insulin resistance after three months of cinnamon supplementation in women with pcos in king abdul-aziz university hospital, jeddah 2019. 3. to determine the effect of cinnamon and cc on menstrual cyclicity, approximated by menstrual frequency, during the study period, in women with pcos in king abdul-aziz university hospital, jeddah 2019 4. to evaluate the quality of life in women with pcos in king abdul-aziz university hospital, jeddah 2019. secondary objectives: * to measure the pregnancy rate in women with pcos in king abdul-aziz university hospital, jeddah 2019 description of study design: the participants will be randomized in 1:1 fashion. allocation concealment will be ensured using similar bottles labeled by letters a and b, to receive either the combination of cinnamon supplement and clomiphene citrate or clomiphene citrate with placebo. first visit: patients will be evaluated during the early follicular phase for progesterone level and homa-ir and quick-i. follow up: 3 months. last visit: patients will be re-evaluated to compare the difference.


Eligibility criteria:
inclusion criteria: * married women aged 18-40 seeking to become pregnant, meeting the rotterdam criteria for polycystic ovary syndrome exclusion criteria: * current pregnancy or lactation. * current use of treatment of infertility. * established diagnosis of diabetes mellitus. * use of insulin-sensitizing treatment within the past three months. * hormonal treatment involving estrogen or progesterone within the past three months. * known hypersensitivity to cinnamon. * use of statin medication. * any other supplements that contain cinnamon within the past month. * bmi \ 35.

Keywords: pcos ovulation cinnamon
bevacizumab and photodynamic therapy in neovascular age related macular degeneration

Conditions: Age Related Macular Degeneration

Summary: the purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.

the neovascular age related macular degeneration(amd) is a important cause of legal blindness in adults older than 50 years. currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. bevacizumab has been reported effective used as intravenous injection for amd. but serious side effects have been reported with the use of this drug in oncologic patients. the intravitreal use has been reported in limited case reports and safety and efficacy should be determined. the purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for amd 4 days after photodynamic therapy with verteporfin

Eligibility criteria:
inclusion criteria: 55 years old neovascular age related acular degeneration subfoveolar neovascular membrane best corrected visual acuity better than 20/200 snellen (1.0 logmar) exclusion criteria: * previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease

Keywords: macular degeneration antibodies angiogenesis inhibitor
a study to evaluate, safety, tolerability, pharmacodynamic (pd) markers and pharmacokinetics (pk) of ap-101 in participants with amyotrophic lateral sclerosis (als)

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this study is to evaluate the safety, tolerability, pk, and pd of ap-101 in participants with fals and sals.


Eligibility criteria:
inclusion criteria: * all participants must adhere to contraception restrictions * female participants of childbearing potential must adhere to contraception restrictions * have possible, clinically probable, clinically probable-laboratory supported or definite familial or sporadic als in accordance with the el-escorial criteria or who have a diagnosis of als as defined by the gold coast criteria; progressive motor impairment documented by history or repeated clinical examination, preceded by normal motor development, and presence of upper and lower motor neuron dysfunction in at least 1 body region or lower motor neuron dysfunction in at least 2 body regions and investigations excluding other conditions * in familial als participants, a confirmed pathogenic superoxide dismutase 1 (sod1) mutation * onset of symptoms (i.e, weakness) within past 24 months prior to screening, at the time of obtaining informed consent * have slow vital capacity (svc) of greater than or equal to (\> or =) 50 percentage (%) of predicted values. participants with svc of \<50% of predicted values may be permitted to enter the open-label extension, based on the opinion of the investigator * absence of bilevel positive airway pressure (bipap)/proportional assist ventilation (pav) \> 4 hours for symptoms attributable to als. use of a cpap for pre-existing conditions will be allowed * if on riluzole, must be on a stable dose. * if on edaravone, must have completed 2 cycles and are expected to remain on the same dose throughout the study * able to provide informed consent which includes compliance with the requirements and restrictions * have venous access sufficient to allow for blood sampling * have clinical laboratory test results within the normal reference range for the population or study site, or results with acceptable deviations that are judged to be not clinically significant by the investigator exclusion criteria: * have participated or currently participating in another clinical trial within 12 weeks of baseline (day 1) * have undergone a tracheostomy for als symptoms * are on nasal intermittent positive pressure ventilation (nippv) \>4 hours per day for the treatment of als related symptoms * have other causes of neuromuscular weakness * have cognitive impairment, severe disease in the cardiovascular, hematological, renal system, neurodegenerative disease, pulmonary disorder, or psychiatric illness * pregnant or nursing women * have been exposed to any antisense treatment targeting sod1 within 6 months of the baseline visit * have undergone stem cell therapy

Keywords: familial amyotrophic lateral sclerosis sporadic amyotrophic lateral sclerosis